BRAF and melanoma: Moreover, combinatorial approaches with standard-of-care therapies have already been explored—such as anti-CSPG4 mAbs combined with the BRAF inhibitor PLX4032 in melanoma—showing synergistic impairment of malignant cell properties and supporting the rationale for combinatorial administration in vivo [186].